To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue Sarcoma

Trial Profile

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue Sarcoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs TAEST 16001 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
  • Indications Osteosarcoma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top